Titan Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary

Titan Pharmaceuticals

16/08/2021 23:45

* Titan Pharmaceuticals Inc  TTNP.OQ  reported a quarterly
adjusted loss of 17 cents​​ per share for the quarter ended in
June. The lone analyst forecast for the quarter was for a loss
of 35 cents per share.
* Revenue fell 66.4% to $445.00 thousand from a year ago; 
analysts expected zero. 
* Titan Pharmaceuticals Inc's reported EPS for the quarter was a
loss of 17 cents​.
* The mean earnings estimate of analysts had risen by
about 60.7% in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Titan Pharmaceuticals Inc shares had fallen by 16.2% this
quarter and lost 33.7% so far this year.
* The company reported a quarterly loss of $1.68 million.
* Wall Street's median 12-month price target for Titan
Pharmaceuticals Inc is $7.00 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
This summary was machine generated August 16 at 10:45 p.m.  ​All
figures in US dollars unless otherwise stated